IMP3 and hepatocellular carcinoma: This is corroborated by the fact that enhanced IMP3 expression was found in over 58% of end-stage renal cell carcinoma tumors (stages III and IV), and more than 40% in hepatocellular carcinoma (HCC) (Li et al., 2015; Pei et al., 2015).